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Abstract
We investigated plasma microRNA (miRNA) profiles associated with variation of hyperglycemia, measured as hemoglobin A 1c (HbA 1c ), in two panels of patients with type 1 diabetes (T1D). Using the HTG Molecular Diagnostics EdgeSeq platform, 2,083 miRNAs were measured in plasma from 71 patients included in a screening panel. Quantitative real-time polymerase chain reaction was used to measure the candidate miRNAs in plasma from 95 patients included in an independent replication panel. We found 10 miRNAs replicated in both panels and four with high statistical significance. The strongest positive correlations with HbA 1c were found with miR-125b-5p (r s = 0.40, p=6.0x10 -5 ) and miR-365a-3p (r s =0.35, p=5.9x10 -4 ). The strongest negative correlations were found with miR-5190 (r s =-0.30, p=0.003) and miR-770-5p (r s =-0.27, p=0.008). Pathway analysis revealed that 50 KEGG pathways were significantly enriched by genes targeted by these 4 miRNAs. The axon guidance signaling pathway was enriched (p<1x10 -7 ) by genes targeted by all 4 miRNAs. And three other pathways (the Rap1 signaling, focal adhesion and neurotrophin signaling) were also significantly enriched but with genes targeted by only by 3 of the identified miRNAs. In conclusion, our study identified 4 circulating miRNAs that were influenced by variation in hyperglycemia. Dis-regulation of these miRNAs, which are associated with hyperglycemia in patients with T1D, may contribute to the development of diabetic complications. However, there are multitudes of possible mechanisms/pathways through which dis-regulation of these miRNAs may impact risk of diabetic complications.
INTRODUCTION
Diabetes mellitus (DM) is characterized by chronic hyperglycemia. Clinical trials in T1D and Type 2 diabetes (T2D) have demonstrated that the degree of hyperglycemia is a major risk factor for the development of late diabetic complications (1, 2) . Various mechanisms have been proposed through which hyperglycemia may impact the development of complications such as retinopathy, nephropathy and neuropathy (3) . These mechanisms include non-enzymatic glycation of proteins, generation of oxidative stress, activation of renin-angiotensin system, DNA methylation and others (3) . Dysregulation of microRNAs (miRNAs) expression resulting from hyperglycemia was recently proposed to be another such mechanism (4) . miRNAs are endogenous short noncoding RNA molecules that regulate gene expression at the post-translational level and modulate a variety of physiological processes in both health and disease (5) . More than 2,500 human miRNAs are known and new ones are continuously being discovered. Mature miRNAs bind to their target mRNA(s) and interfer with their translation (6) . As such, elevated levels of miRNAs result in lower expression levels of their targeted gene(s), and likely decrease protein levels as well. Conversely, lower levels of miRNA should result in higher levels of their target gene(s)/protein(s). At least 60% of human protein-coding genes are targeted/regulated by miRNAs (7) . miRNA profiles associated with hyperglycemia in diabetes in humans have not yet been studied in a comprehensive way. Although some previous reports investigated associations between circulating miRNAs and hyperglycemia in patients with T2D (8; 10), these studies were limited in the scope of profiling and used variable normalizations methods and their results remain controversial. Additionally, few reports focused on the effect of hyperglycemia on specific miRNA profiles. For example let-7c-5p and let-7a-5p were shown to be negatively correlated with HbA 1c in serum obtained from children with T1D (11) and miR-375 were reported to be increased in plasma from patients with T1D compared to individuals with normal glucose tolerance (12; 13).
The aim of this study was to examine profiles of circulating miRNAs according to variation of hyperglycemia measured by HbA 1c levels in patients with T1D. Using the HTG Molecular Diagnostics EdgeSeq platform that measured the majority of known circulating miRNAs, we determined concentration of 2,083 miRNAs in plasma obtained from patients included in a screening panel. miRNAs correlated with HbA 1c in this panel were examined further for similar associations in plasma obtained from patients included in the replication panel using quantitative real-time polymerase chain reaction. The new miRNAs strongly associated with variation in HbA 1c were subjected to bioinformatics analysis to identify genes and pathways targeted by these miRNAs.
RESEARCH DESIGN and METHODS
The study design and methods used are outlined in Figure 1 . All subjects included in this research were recruited as part of the Joslin Kidney Studies. Study protocols on recruitment and examination of patients in the Joslin Kidney Study and related consent procedures were approved by the Joslin Diabetes Center Institutional Review Board.
Screening panel
Our screening panel consisted of 71 patients randomly selected from the participants in the Second Joslin Kidney Study (2 nd JKS) with baseline clinical data, baseline measurements of HbA1c and baseline specimens of plasma available for use in this study (14) . Briefly, the 2 nd JKS is a longitudinal investigation on the natural history of early diabetic nephropathy in non-proteinuric patients (n=660) with T1D attending the Joslin Clinic between 2003 and 2006.
More information about study enrollment and protocols to examine these patients was provided in previous publications (14; 15) .
miRNA expression profiling in the screening panel
To determine concentration of 2,083 known miRNAs in plasma from patients in our screening panel, we applied HTG's EdgeSeq technology (HTG Molecular Diagnostics, Inc, Tucson, AZ, USA), a new next-generation sequencing-based miRNA profiling platform (16; 17) . Fifteen µl aliquots of plasma from 71 patients were submitted to HTG Molecular Diagnostics for analysis.
The samples were run on an EdgeSeq Processor using the EdgeSeq miRNA whole transcriptome assay. After the processor step, samples were individually barcoded by adding sequence adaptors and molecular barcodes to each plasma sample. Barcoded samples were pooled, individually purified and sequenced on the Illumina NextSeq 500 Sequencing platform using a High Output, 75 cycle, v2 kit with two index read. Data were retrieved from the sequencer in the form of FASTQ files and processed using the EdgeSeq Parser software (HTG Molecular Diagnostics, Inc.).
Normalization of miRNA expression data in the screening panel
Normalization of miRNA expression data was performed using the edgeR (Version 3.12.1) (18) and limma (Version 3.26.9) (19) packages from Bioconductor in R. As detectable miRNAs we considered miRNAs that had expression levels of >1 counts per million (CPM) in more than half of our samples (>36). We then applied quantile normalization, a non-scaling approach that forces the distribution of read counts in all experimental samples to be equivalent and assumes that i) most target miRNAs are not differentially expressed and ii) that the true expression distribution of miRNAs is similar across all samples (20) .
Replication panel
We selected randomly 95 patients from among those participating in the Joslin Proteinuria
Cohort as a replication panel. Briefly, Proteinuria Cohort comprised 424 patients who developed proteinuria while attending the Joslin Clinic between 1991 and 2004 (21) . These patients were enrolled into a long-term follow-up study (22 
RNA isolation and quantitative real time polymerase chain reaction (qRT-PCR)
Total RNA was isolated from 60µl plasma samples from members of the replication panel using the Qiagen's miRNeasy Serum/Plasma kit (Qiagen, Valencia, CA) according to the manufacturer's protocol and as already published (23) . Candidate miRNAs identified in the screening panel were used to design a custom miScript miRNA PCR Array (Qiagen). As some assays were not available on this platform, our custom miScript miRNA PCR Array included 48 miRNAs identified in the screening panel as well as several positive control miRNAs.
Reverse transcription of RNA isolated from plasma was performed using the miScript II RT Kit with miScript HiSpec Buffer (Qiagen). One and a half µl of isolated RNA was used to prepare a 10µl reverse transcription reaction as specified by the manufacturer. The pre-amplification was 
Pathway analysis
To predict the target genes for the candidate miRNAs, we used the open-access web-server miRWALK2.0 (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2) that integrates 12 target prediction algorithms (25) . To increase prediction accuracy, we required that putative target genes be identified by at least 6 of the 12 algorithms included in miRWALK2.0. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was performed for overlapped genes using DAVID (https://david.ncifcrf.gov/) (26) . A Fisher exact test p-value <0.01 was used to identify significantly targeted pathways in KEGG and enriched gene target pathways obtained from these databases.
Statistical Analysis
All statistical analyses were conducted using SAS for Windows, version 9.4 (SAS Institute, Cary, NC) or R (Version 3.2.4). Correlations between HbA 1c and candidate miRNA expression levels were estimated by Spearman's rank correlation test.
For further assessment of levels of candidate miRNAs, patients were divided into tertiles based on HbA 1c levels and data were compared across tertiles. Group-wise comparisons of differences in miRNA levels were assessed by non-parametric one way ANOVA and Dwass, Steel, Critchlow-Fligner test as appropriate. P-values <0.05 were considered statistically significant.
RESULTS

Clinical characteristics of study panels
Clinical characteristics for patients included in the screening and the replication panels are presented in Table 1 . Importantly, both studies included patients with a very broad range of hyperglycemia. The interquartile range of HbA 1c was <7.9% and >9.2% in the screening panel and <8.3% and >10.1% in the replication panel. Relative to patients in the screening panel, the replication panel included more men, these patients were younger, had shorter duration of diabetes, had slightly higher systolic and diastolic blood pressure, had lower BMI, and the majority had microalbuminuria or proteinuria. In addition, patients in both panels had normal eGFR, although it was slightly lower in those included in the replication panel.
Screening for candidate miRNAs using the EdgeSeq platform
Using the EdgeSeq platform, expression profiles were measured for 2,083 miRNAs in patients included in the screening panel. After filtering out non-detectable miRNAs, we normalized the data using quantile normalization with sample weights and examined correlations between these miRNA expression levels and HbA 1c levels using Spearman's rank correlation test. A total of 54 miRNAs were found to be correlated with HbA 1c at p-value <0.01 (Supplemental Table 1 ).
Examination of the candidate miRNAs in replication panel using qRT-PCR
Among the 54 candidate miRNAs identified in the screening panel, 48 were assayed in the replication panel. Among these 48 candidate miRNAs, only 26 miRNAs were detected in more than half of the study patients (>48 out of 95 patients). The rest of the miRNAs were detected in a fewer number of patients or not at all (see Supplemental Table 1 ). We performed Spearman rank correlation testing of these 26 miRNAs and HbA 1c levels. Ten miRNAs were correlated with HbA 1c at p<0.05 (Table 2) (r s =-0.27, p=0.008) had the strongest and most significant negative correlation with HbA 1c .
Interestingly, plasma levels of miR-125b-5p and miR-365a-3p were strongly and positively correlated with each other as were miR-5190 and miR-770-5p (r s >0.65, p<10 -6 ). On the other hand correlation among the first two and the two others was negative and much weaker (r s =-0.20
and -0.40, p<0.05) (Supplemental Table 2 ).
The correlation between HbA 1c and these 4 candidate miRNAs remained statistically significant after adjustment for age, BMI, systolic blood pressure, and ACR. Spearman correlation coefficients were as follows; r s =0.34, p=0.0025 for miR-125b-5p; r s =0.31, p=0.005 for miR-365a-3p; r s =-0.26, p=0.019 for miR-5190; and r s =-0.30, p=0.0074 for miR-770-5p. The other six miRNAs were less correlated with HbA 1c in the replication study and were not analyzed further.
Distribution of plasma levels of the 4 candidate miRNAs across tertiles of HbA 1c
To further examine the relationship between the 4 candidate miRNAs and hyperglycemia, the distribution of each of these miRNAs was plotted across to tertiles of HbA 1c levels in the screening and in the replication panels separately. Table   3A and 3B. In the screening panel, the highest tertile sub-group was slightly older and had slightly higher eGFR than the lowest tertile sub-group. However, these 2 covariates were not significantly different among the tertiles in the replication panel.
As shown in Figure 2A , among patients in the screening panel, plasma levels of miR-125b-5p
and miR-365a-3p increased with tertiles of HbA 1c . Whereas the increase of plasma levels of miR-125b-5p appears to be dose dependent, miR-365a-3p levels were only significantly increased in the highest HbA 1c tertile (HbA 1c >8.9%). In contrast, plasma levels of miR-5190 and miR-770-5p decreased in a dose dependent way with increasing tertiles of HbA 1c (i.e., worsening hyperglycemia).
As shown in Figure 2B , among patients in the replication panel, despite a very different method of determining concentrations of miRNAs, the patterns of association of the 4 candidate miRNAs according to the tertiles of HbA 1c were similar as in patients in the screening panel. Figure 2B also shows the distribution of plasma levels of the 4 candidate miRNAs obtained from 30 non-diabetic controls using qRT-PCR. Plasma levels of miR-125b-5p were very low in the controls (at detection limits) in comparison with increasing levels of HbA 1c in patients with T1D
(p<0.00001). Plasma levels of miR-365a-3p were low but well detected in non-diabetic controls and similar as in the 1 st tertile of HbA 1c . On the other hand plasma levels of miR-5190 were high in non-diabetic controls and similar as in the 1 st tertile of HbA 1c . The levels of this miRNA were significantly lower in the 2 nd and 3 rd tertile of HbA 1c . Plasma levels of miR-770-5p in non-diabetic controls were the most contrasting. They were very low whereas levels of this miRNA were high in the 1 st tertile (best glycemic control) and decreased in a dose dependent way with increasing HbA 1c .
Correlation of plasma levels of the 4 candidate miRNAs with clinical characteristics
The 4 candidate miRNAs showed strong correlation with HbA1c levels in both panels as shown above in Table 2 and Figure 2 . In the screening panel the levels of miRNAs were not correlated at all with other clinical characteristics such as BMI, eGFR, urinary albumin excretion measured as ACR, and systolic blood pressure (Data not shown). In the replication panel variation of BMI and eGFR were not associated with variation in miRNAs. In contrast, all 4 miRNAs were significantly associated with ACR and systolic blood pressure (See supplemental Table 3 ). These associations, however, did not change the correlations of these miRNAs with HbA1c (See supplemental Table 3 ).
Target genes and target pathways for the 4 candidate miRNAs
Using miRWalk2.0 software, 5,566 predicted genes were identified by at least 6 prediction algorithms that were targeted by the 4 candidate miRNAs highly correlated with HbA 1c . The numbers of genes targeted by each of the miRNAs are shown in boxes in Figure 3A . Since many of the genes were targeted by multiple miRNAs, the total of unique genes was only 4,391. The multiple color Venn Diagram presented in Figure 3A shows the distribution of these genes according to the candidate miRNAs that targeted them.
To identify pathways enriched with these genes, a KEGG pathway analysis was performed. After eliminating cancer related pathways, this analysis identified 29 pathways enriched with genes targeted by miR-125b-5p, 27 by miR-365a-3p, 13 by miR-770-5p and 13 by miR-5190 (a total 82 pathways, Supplemental Table 5 ). Many of the pathways, however, overlapped so in total there were 50 unique pathways enriched at statistical significance of p<0.01. Figure 3B shows distribution of the enriched pathways as a Venn Diagram according to the candidate miRNAs, and Table 3 ). There were 8 other pathways enriched with genes targeted by 3 miRNAs, the most statistically significant of which were the Rap1 signaling pathway (p<7.5x10 -8 ), focal adhesion pathway (p<1.6x10
) and neurotrophin signaling pathway (p<6.3x10 -8 ). Eleven pathways were enriched with genes that were targeted by 2 miRNAs. The remaining 30 pathways were enriched with genes targeted only by one miRNA and the degree of enrichment was less statistically significance (see supplemental Table 6 ).
Genes targeted by the 4 candidate miRNAs in the Axon Guiding Signaling Pathway.
To illustrate the complexity of the possible effects of the candidate miRNAs, we analyzed genes targeted by these miRNAs in the axon guiding signaling pathway. In the KEGG database, this pathway consists of 129 distinct genes. Among these genes, 57 are predicted to be targeted and regulated by the 4 candidate miRNAs, while only 29.3 genes were expected if there was no enrichment (p< 1.0x10 -7 for difference between targeted and expected) ( Table 3 ). Table 4 lists target genes grouped according to candidate miRNAs. It is striking that a large proportion of these genes had similar names disregarding the grouping. Furthermore, the majority of these target genes belonged to the same gene families such as EPHRINs, SEMPAPHORINs, NETRINs, and SLITs. The target genes included ligands as well as receptors, and activators and activated genes.
DISCUSSION
Our study is the first to comprehensively examine nearly all known circulating miRNAs for association with variation in hyperglycemia in T1D. Using a new next-generation sequencing-based miRNA platform, we measured plasma levels of 2,083 known miRNAs in exploratory panel and found that 54 miRNAs correlated with hyperglycemia. Among these miRNAs, 10 were confirmed by qRT-PCR in an independent replication panel and 4 of them, miR-125b-5p, miR-365a-3p, miR-5190 and miR-770-5p, showed very significant correlation with HbA 1c levels. These correlations remained significant disregarding adjustment for various clinical characteristics including presence or absence of kidney complications. Bioinformatics analyses showed that these 4 candidate miRNAs target the expression of more than 4,000 genes/proteins that may impact 50 KEGG pathways. Four of these pathways had the highest statistical support for enrichment with genes targeted by these putative hyperglycemia-regulated miRNAs. These include the axon guidance signaling pathway, Rap1 signaling pathway, focal adhesion pathway and neurotrohpin signaling pathway. Overall, our study showed that hyperglycemia impacts expression of a relatively few specific circulating miRNAs which target thousands of genes and many dozens of pathways. The interpretation and experimental validation of our findings creates a formidable challenge considering that our study measured circulating miRNAs and not intracellular in humans. Furthermore, not all human miRNAs are present in animals. Following we discuss our findings in the context of the limited literature regarding the pathways and miRNAs involved.
The axon guidance signaling pathway contains 127 genes/proteins and, in our study, 57 of these genes were predicted to be targeted by the 4 candidate miRNAs (only 29 genes would be expected by chance). This pathway is involved in the formation of neuronal network and it is guided by several guidance factors/proteins, including such ligands as Semaphorins, Ephrins, Slits and Netrins and their corresponding receptors neurophilin, Eph, Robo1-4 and UNC5. Singh et al. reported that mRNAs for genes encoding axon guidance signaling pathway were upregulated in hyperglycemic state in human endothelial cells (27) , and recent reports implicated some of these proteins and this pathway in the development of diabetic retinopathy and nephropathy (28; 29).
The Rap1 signaling pathway contains 210 genes/proteins; 78 of these genes are predicted to be targeted by three putative hyperglycemia-regulated miRNAs identified in our study (44 would have been expected by chance). Rap1 is a small GTPase that controls diverse processes, including cell adhesion, cell-cell junction formation and cell polarity. In contrast to the results of our pathway analysis that showed that all the putative hyperglycemia-regulated miRNAs might target a large number of genes in multiple pathways, many of the previous publications aimed on studying single miRNAs and focused on limited downstream effects. For example studies on miR-125b have focused on its impact on the regulation of specific downstream gene targets. Villeneuve et al. reported that miR-125b levels were up-regulated in the diabetic db/db vascular smooth muscle cells (VSMC) compared to control mice and that this miRNA was able to target and down-regulate Suv39h1, a histone methyltransferase that mediates histone H3-lysine-9 trimethylation (H3K9me3) (35) . The authors also found that histone H3K9me3 levels were decreased at the promoters of key inflammatory genes, interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1). Other studies have reported that miR-125b-5p expression is involved in the immune responses to viral infection (36) .
Interestingly, plasma miR-125b-5p levels and hyperglycemia were considered risk factors for poor prognosis in children with viral encephalitis (37) . No similar research has been done regarding the biology of the other putative hyperglycemia-regulated miRNAs identified in our study, i.e. miR-365a-3p, miR-5190 and miR-770-3p. hyperglycemia-regulated miRNAs identified in our study were secreted from certain cells or whether they are derived from damaged cells, circulating miRNA profiles can be useful not only to better understand the pathogenesis of diabetes, but also to identify novel therapeutic targets to prevent or treat diabetic complications.
Finally, some strengths and limitation of our study need to be considered. To increase the reliability of our findings, we implemented a two-stage study design. In the first stage candidate miRNAs were searched in a comprehensive way using the EdgeSeq platform to sequence and quantify 2,083 miRNAs in the screening panel. In the second stage due to limited resources, we used a qRT-PCR to validate the initial findings using the replication panel. Apparently the latter approach was not sensitive enough to detect nearly half of the candidate miRNAs detected in the first stage. At this time we cannot establish the reasons for the discrepancies. However, it is possible that extraction of RNA from plasma to run qRT-PCR may result in a loss of certain species of miRNAs. This would suggest that more candidate miRNAs may have been regulated by hyperglycemia than our study identified. Furthermore, by using qRT-PCR and studying non-diabetic controls we showed that 2 out of 4 candidate miRNAs examined had very low expression compared to diabetic patients. The biology for these differences is unknown but was most likely unrelated to level of hyperglycemia. Additionally, our study is a clinical observation and we could not investigate the mechanisms of regulation of miRNA expression, regulation of expression at the locus of each miRNA, and regulation through degradation/modification of these miRNAs. Further studies are necessary to investigate these issues.
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